These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 26576639)
1. PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma. Yu G; Yu W; Jin G; Xu D; Chen Y; Xia T; Yu A; Fang W; Zhang X; Li Z; Xie K Mol Cancer; 2015 Nov; 14():193. PubMed ID: 26576639 [TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism. Shiroki T; Yokoyama M; Tanuma N; Maejima R; Tamai K; Yamaguchi K; Oikawa T; Noguchi T; Miura K; Fujiya T; Shima H; Sato I; Murata-Kamiya N; Hatakeyama M; Iijima K; Shimosegawa T; Satoh K Cancer Sci; 2017 May; 108(5):931-940. PubMed ID: 28235245 [TBL] [Abstract][Full Text] [Related]
3. Knockdown of pyruvate kinase type M2 suppresses tumor survival and invasion in osteosarcoma cells both in vitro and in vivo. Yuan Q; Yu H; Chen J; Song X; Sun L Exp Cell Res; 2018 Jan; 362(1):209-216. PubMed ID: 29155364 [TBL] [Abstract][Full Text] [Related]
4. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599 [TBL] [Abstract][Full Text] [Related]
5. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma. Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265 [TBL] [Abstract][Full Text] [Related]
6. MIR210HG regulates glycolysis, cell proliferation, and metastasis of pancreatic cancer cells through miR-125b-5p/HK2/PKM2 axis. Yu T; Li G; Wang C; Gong G; Wang L; Li C; Chen Y; Wang X RNA Biol; 2021 Dec; 18(12):2513-2530. PubMed ID: 34110962 [TBL] [Abstract][Full Text] [Related]
7. Both high expression of pyruvate kinase M2 and vascular endothelial growth factor-C predicts poorer prognosis in human breast cancer. Lin Y; Liu F; Fan Y; Qian X; Lang R; Gu F; Gu J; Fu L Int J Clin Exp Pathol; 2015; 8(7):8028-37. PubMed ID: 26339369 [TBL] [Abstract][Full Text] [Related]
8. PKM2 gene regulates the behavior of pancreatic cancer cells via mitogen-activated protein kinase pathways. Feng J; Ma T; Ge Z; Lin J; Ding W; Chen H; Zhu W; Zhou S; Tan Y Mol Med Rep; 2015 Mar; 11(3):2111-7. PubMed ID: 25411978 [TBL] [Abstract][Full Text] [Related]
9. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway. Fukuda S; Miyata H; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1461-8. PubMed ID: 25808097 [TBL] [Abstract][Full Text] [Related]
10. Knockdown of PKM2 Suppresses Tumor Growth and Invasion in Lung Adenocarcinoma. Sun H; Zhu A; Zhang L; Zhang J; Zhong Z; Wang F Int J Mol Sci; 2015 Oct; 16(10):24574-87. PubMed ID: 26501265 [TBL] [Abstract][Full Text] [Related]
11. MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer. Tang R; Yang C; Ma X; Wang Y; Luo D; Huang C; Xu Z; Liu P; Yang L Oncotarget; 2016 Feb; 7(5):5972-84. PubMed ID: 26745603 [TBL] [Abstract][Full Text] [Related]
12. Knockdown of Pyruvate Kinase M2 Inhibits Cell Proliferation, Metabolism, and Migration in Renal Cell Carcinoma. Dey P; Son JY; Kundu A; Kim KS; Lee Y; Yoon K; Yoon S; Lee BM; Nam KT; Kim HS Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717694 [TBL] [Abstract][Full Text] [Related]
13. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma. Chen Z; Lu X; Wang Z; Jin G; Wang Q; Chen D; Chen T; Li J; Fan J; Cong W; Gao Q; He X Oncotarget; 2015 Feb; 6(4):2538-48. PubMed ID: 25576919 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of Pyruvate Kinase Type M2 (PKM2) Promotes Ovarian Cancer Cell Growth and Survival Via Regulation of Cell Cycle Progression Related with Upregulated CCND1 and Downregulated CDKN1A Expression. Zheng B; Liu F; Zeng L; Geng L; Ouyang X; Wang K; Huang Q Med Sci Monit; 2018 May; 24():3103-3112. PubMed ID: 29752805 [TBL] [Abstract][Full Text] [Related]
15. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis. Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689 [TBL] [Abstract][Full Text] [Related]
16. MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma. Chen J; Yu Y; Chen X; He Y; Hu Q; Li H; Han Q; Ren F; Li J; Li C; Bao J; Ren Z; Duan Z; Cui G; Sun R Cell Prolif; 2018 Dec; 51(6):e12510. PubMed ID: 30105813 [TBL] [Abstract][Full Text] [Related]
17. Human steroid sulfatase enhances aerobic glycolysis through induction of HIF1α and glycolytic enzymes. Shin S; Kwon YJ; Ye DJ; Baek HS; Kwon TU; Kim D; Chun YJ Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2464-2474. PubMed ID: 31195119 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of Proliferation, Migration, and Invasion by Knockdown of Pyruvate Kinase-M2 (PKM2) in Ovarian Cancer SKOV3 and OVCAR3 Cells. Miao Y; Lu M; Yan Q; Li S; Feng Y Oncol Res; 2016 Oct; 24(6):463-475. PubMed ID: 28281967 [TBL] [Abstract][Full Text] [Related]
19. Leptin stimulates the epithelial‑mesenchymal transition and pro‑angiogenic capability of cholangiocarcinoma cells through the miR‑122/PKM2 axis. Peng C; Sun Z; Li O; Guo C; Yi W; Tan Z; Jiang B Int J Oncol; 2019 Jul; 55(1):298-308. PubMed ID: 31115511 [TBL] [Abstract][Full Text] [Related]
20. Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species. Yokoyama M; Tanuma N; Shibuya R; Shiroki T; Abue M; Yamamoto K; Miura K; Yamaguchi K; Sato I; Tamai K; Satoh K Int J Oncol; 2018 Mar; 52(3):881-891. PubMed ID: 29393401 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]